Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | DTYMK | P23919 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 3/20 | 0.41 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46600 | 0.87 | DDB1 (0.49) | DDB1CRBNDTYMKKITPARP1 | |
| SCHEMBL30339672 | 0.84 | KIT (0.48) | DDB1CRBNDTYMKKITPOLB | |
| SCHEMBL24101723 | 0.84 | KIT (0.48) | DDB1CRBNDTYMKKITPOLB | |
| SCHEMBL31119374 | 0.83 | MTHFD2 (0.49) | PARP1MTHFD2 | |
| SCHEMBL24914501 | 0.83 | KIT (0.42) | DDB1CRBNKITPARP1TNKS2 | |
| SCHEMBL24914458 | 0.82 | MTHFD2 (0.60) | DDB1CRBNPARP1TNKS2PARP2 | |
| SCHEMBL2485934 | 0.81 | MKNK1 (0.46) | DDB1CRBNPARP1TNKS2PARP2 | |
| SCHEMBL2484902 | 0.79 | MKNK1 (0.46) | DDB1CRBNPARP1TNKS2PARP2 | |
| SCHEMBL23580395 | 0.78 | ESR2 (0.42) | DDB1CRBNPARP1TNKS2PARP2 | |
| SCHEMBL24914504 | 0.77 | MKNK1 (0.42) | DDB1CRBNPARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025217420-A1 | PYRIDINONE COMPOUNDS, METHODS AND USES THEREOF | ZENO MANAGEMENT, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| CN-115677719-B | Aryl heterocyclic compound and preparation method and application thereof | 复旦大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-119343340-A | Methods of preparing modified BTK inhibitors | 普林斯匹亚生物制药公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2024088109-A1 | ARYL HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 复旦大学 | 2024-05-02 | — | — | WO | disclosed |
| CN-115960074-A | Fluorine-containing ferroelectric liquid crystal molecules containing heteroatom hexatomic alicyclic ring and synthesis method thereof | 华南理工大学 | 2023-04-14 | — | — | CN | disclosed |
| WO-2023284807-A1 | COMPOUND CONTAINING TETRAHYDRONAPHTHYRIDONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2023-01-19 | — | — | WO | disclosed |
| WO-2023284807-A1 | COMPOUND CONTAINING TETRAHYDRONAPHTHYRIDONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2023-01-19 | — | — | WO | disclosed |
| CN-115611896-A | Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof | 中国药科大学 | 2023-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | BTK, TEC, SYK | DDB1 2030/4885CRBN 1630/4885DTYMK 400/4885 |
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRCP, TMPRSS15, WEE1 | DDB1 3529/4885CRBN 1365/4885DTYMK 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.